NasdaqGS:PBYI

Stock Analysis Report

Executive Summary

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care.

Snowflake

Fundamentals

Adequate balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Puma Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-29.2%

PBYI

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-82.6%

PBYI

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: PBYI underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: PBYI underperformed the US Market which returned 6.7% over the past year.


Share holder returns

PBYIIndustryMarket
7 Day-29.2%0.8%1.0%
30 Day-36.9%-3.9%-1.8%
90 Day-33.9%-3.5%-1.8%
1 Year-82.6%-82.6%-7.5%-8.3%9.1%6.7%
3 Year-86.4%-86.4%13.6%9.6%46.1%36.6%
5 Year-96.8%-96.8%3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Puma Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Puma Biotechnology undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: PBYI ($7.13) is trading below our estimate of fair value ($59.4)

Significantly Undervalued: PBYI is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: PBYI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PBYI is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate PBYI's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: PBYI is overvalued based on its PB Ratio (12.7x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Puma Biotechnology expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

71.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: PBYI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: PBYI is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: PBYI's loss is forecast to worsen by 0% next year.

Revenue vs Market: PBYI's revenue (12.6% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: PBYI's revenue (12.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: PBYI is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Puma Biotechnology performed over the past 5 years?

-0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PBYI is unprofitable, and losses have increased over the past 5 years at a rate of -0.2% per year.

Accelerating Growth: Unable to compare PBYI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PBYI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: PBYI has a negative Return on Equity (-424.45%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PBYI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PBYI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Puma Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: PBYI's short term assets ($157.6M) exceeds its short term liabilities ($91.7M)

Long Term Liabilities: PBYI's short term assets (157.6M) exceeds its long term liabilities (126.4M)


Debt to Equity History and Analysis

Debt Level: PBYI's debt to equity ratio (429.2%) is considered high

Reducing Debt: Insufficient data to determine if PBYI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: PBYI has a low level of unsold assets or inventory.

Debt Coverage by Assets: PBYI's debt is covered by short term assets (assets are 1.686840x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PBYI has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PBYI is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 35.5% per year.


Next Steps

Dividend

What is Puma Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate PBYI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PBYI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PBYI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PBYI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PBYI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Puma Biotechnology's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Alan Auerbach (49yo)

8yrs

Tenure

US$6,152,550

Compensation

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman, Chief Executive Officer and President since October 4, 2011 and serves as its Secretary. Mr. Auerbach is ...


CEO Compensation Analysis

Compensation vs. Market: Alan's total compensation ($USD6.15M) is about average for companies of similar size in the US market ($USD1.17M).

Compensation vs Earnings: Alan's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.1yrs

Average Tenure

52yo

Average Age

Experienced Management: PBYI's management team is considered experienced (3.1 years average tenure).


Board Age and Tenure

4.2yrs

Average Tenure

54yo

Average Age

Experienced Board: PBYI's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: PBYI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$91503 Oct 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares91
Max PriceUS$10.05
SellUS$5,02703 Oct 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares504
Max PriceUS$9.97
SellUS$19,54025 Sep 19
Douglas Hunt
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Regulatory Affairs
Shares1,711
Max PriceUS$11.42
SellUS$5,31306 Sep 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares524
Max PriceUS$10.14
SellUS$96005 Sep 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares95
Max PriceUS$10.11
SellUS$4,66805 Aug 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares517
Max PriceUS$9.03
SellUS$84605 Aug 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares94
Max PriceUS$9.00
SellUS$6,32603 Jul 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares495
Max PriceUS$12.78
SellUS$1,13703 Jul 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares89
Max PriceUS$12.78
SellUS$1,32606 Jun 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares88
Max PriceUS$15.07
SellUS$7,33205 Jun 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares483
Max PriceUS$15.18
SellUS$2,75206 May 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares85
Max PriceUS$32.38
SellUS$15,44506 May 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares477
Max PriceUS$32.38
SellUS$3,14903 Apr 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares88
Max PriceUS$35.78
SellUS$17,57303 Apr 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares491
Max PriceUS$35.79
SellUS$3,40222 Mar 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares88
Max PriceUS$38.66
SellUS$19,15622 Mar 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares496
Max PriceUS$38.62
SellUS$2,40506 Feb 19
Charles Eyler
EntityIndividual
Shares87
Max PriceUS$27.64
SellUS$2,47206 Feb 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares89
Max PriceUS$27.77
SellUS$9,59106 Feb 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares345
Max PriceUS$27.80
SellUS$91,44404 Jan 19
Alan Auerbach
EntityIndividual
Role
Chief Executive Officer
Founder
Shares4,424
Max PriceUS$20.67
SellUS$25,01104 Jan 19
Charles Eyler
EntityIndividual
Shares1,210
Max PriceUS$20.67
SellUS$25,01104 Jan 19
Richard Bryce
EntityIndividual
Role
Chief Scientific Officer
Chief Medical & Scientific Officer
Shares1,210
Max PriceUS$20.67

Ownership Breakdown


Management Team

  • Alan Auerbach (49yo)

    Founder

    • Tenure: 8yrs
    • Compensation: US$6.15m
  • Mariann Ohanesian

    Senior Director of Investor Relations

    • Tenure: 7.9yrs
  • Steven Lo (52yo)

    Chief Commercial Officer

    • Tenure: 4.1yrs
    • Compensation: US$2.24m
  • Richard Bryce (62yo)

    Chief Medical & Scientific Officer

    • Tenure: 2.2yrs
    • Compensation: US$1.89m
  • Douglas Hunt (54yo)

    Senior Vice President of Regulatory Affairs

    • Tenure: 1.8yrs
    • Compensation: US$6.75m
  • Charon Spencer

    Vice President of Human Resources

    • Tenure: 0yrs
  • Maximo Nougues (50yo)

    CFO & Principal Accounting Officer

    • Tenure: 0.9yrs
    • Compensation: US$2.28m

Board Members

  • Jay Moyes (65yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$385.52k
  • Mike Miller (62yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$1.24m
  • Troy Wilson (50yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$355.52k
  • Alan Auerbach (49yo)

    Founder

    • Tenure: 8yrs
    • Compensation: US$6.15m
  • Frank Zavrl (53yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$358.02k
  • Adrian Senderowicz (55yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$353.02k

Company Information

Puma Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Puma Biotechnology, Inc.
  • Ticker: PBYI
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$277.336m
  • Shares outstanding: 38.90m
  • Website: https://www.pumabiotechnology.com

Number of Employees


Location

  • Puma Biotechnology, Inc.
  • 10880 Wilshire Boulevard
  • Suite 2150
  • Los Angeles
  • California
  • 90024
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PBYINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2012
0PBDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2012

Biography

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatm ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:42
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)